Google Inc vs Eli Lilly And Co — how do they compare? Google Inc trades at $348.4 (market cap $4.24T), while Eli Lilly And Co trades at $1,177.57 (market cap $1.04T). The key difference: Google Inc is far larger — about 4.1× Eli Lilly And Co's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Eli Lilly And Co for 93 Days on average.
| GOOG | LLY | |
|---|---|---|
Market Cap | $4.24T | $1.04T |
Volume | 13,937,902 | 3,064,878 |
Sector | Media | Health |
52-Week High | $399.06 | $1.28K |
52-Week Low | $237.49 | $799.57 |
Typical Hold Time | 137 Days | 93 Days |
Enterprise Value | $4.13T | $1.09T |
Dividend Yield | 0.26% | 0.59% |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $347.86, up 0.14% with strong technical momentum above key support levels. The stock shows robust fundamentals with revenue growth accelerating to $402.84B in 2025 and net income margins expanding to 32.8%. Recent earnings beats and a bullish analyst consensus at 87% buy ratings support the positive outlook, though elevated capital expenditures and regulatory scrutiny present near-term headwinds.
Alphabet's outlook remains favorable with AI-driven cloud growth and consistent earnings outperformance. The stock trades at a reasonable 17.3 P/E with 34% upside to the $435.24 consensus target. Key risks include massive AI infrastructure spending impacting cash flow and ongoing regulatory litigation. The technical setup suggests continued momentum toward resistance at $352-$354.
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →